Breast Cancer

Additionally, the 2-time dependent variables, dose reduction, and relative dose intensity 2 (RDI2) were included in the respective model as covariates to explore the connection to overall survival.

Further sensitivity analyses to control for family alcohol consumption, family history, liver disease, and smoking, finds no convincing evidence that these factors affected the results.

Experts discuss the role of pharmacists in improving screening rates for breast cancer, how they can support patients, and improve outcomes.

Ribociclib plus fulvestrant achieved a median overall survival of 67.6 months in the first line setting for postmenopausal women with HR-positive/HER2-negative advanced breast cancer.

Discovery has the potential to also benefit treatment choices, investigators from Georgetown Lombardi Comprehensive Cancer Center say.

The data show that the 10-year survival rate of patients with breast cancer who survived Hurricane Katrina was much lower than those who did not face a major weather event.

Medicaid expansion implementation was associated with a decrease in the number of uninsured patients from 6.7% pre-expansion to 3.6% post-expansion.

Numbers have remained below prepandemic levels.

Investigators focus on understanding the difference in the microenvironments that surround cancer cells in the primary tumor versus the sites where it metastasizes.

Peptide-targeted radionuclide therapy FAP-2286 (Clovis Oncology) showed potent affinity for human fibroblast activation protein by biochemical and cell-based assays.

Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.

Study finds that health care providers need to reinforce the importance of annual mammograms among patients who survived breast cancer.

Alpelisib is the first FDA-approved treatment for PROS, which is a range of rare conditions characterized by overgrowths and blood vessel anomalies.

21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.

Olaparib (Lynparza) was found to significantly improve overall survival in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

The median survival time of patients was 12 months compared with 7 in the control group, the analysis demonstrates.

Researchers found that in a program of biennial screening of women aged 50 to 74 years, approximately 1 in 7 screen-detected breast cancer cases would be overdiagnosed.

Lakyn Husinka, PharmD, discussed new treatment options and pharmacists' role in treating patients with breast cancer.

Results of studies show that women with obesity who get these weight loss procedures often also have preventative benefits.

Women who get these screenings starting at aged 30 to 35 years could cut their cancer mortality by more than 50%, new study results show.

Dalpiciclib added to fulvestrant (Faslodex) was found to significantly prolong progression-free survival compared with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

An emerging focus is aligning targeted, safe, and effective therapies with patient goals.

New study results show that the drugs, which block estrogen production, are more effective for premenopausal and postmenopausal women.

Christopher Mast, MD, vice president of clinical informatics at Epic, explains his outlook for the future in the field of oncology in light of the ongoing delays in cancer screenings rates.

Christopher Mast, MD, vice president of clinical informatics at Epic, explains the level to which cancer screening rates would need to rise to meet pre-pandemic rates.

Results from a clinical trial led by investigators at the National Cancer Institute show that 28 of 42 women with tumors generated a reaction.

Christopher Mast, MD, vice president of clinical informatics at Epic, discusses research that showed that cancer screening rates in 2021 rebounded from the low rates at the start of the pandemic, but not significantly.

Abemaciclib (Verzenio) was recently approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.

Trastuzumab deruxtecan is a HER2-directed antibody drug conjugate being developed by both AstraZeneca and Daiichi Sankyo.

Knocking down MAPK4 resulted in the cells’ increased sensitivity to PI3K inhibitors and reduced breast cancer growth.